Principles of surgical treatment of malignant melanoma

Surgical Clinics of North America

Volumn 94, Issue 5, 2014, Pages 973-988

  Kimbrough, Charles W ^a   McMasters, Kelly M ^a   Davis, Eric G ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Completion lymphadenectomy; Melanoma; Sentinel lymph node biopsy; Wide local excision

Indexed keywords

ISOSULFAN BLUE;

CANCER RECURRENCE; CUTANEOUS MELANOMA; HUMAN; LYMPH NODE; LYMPH NODE DISSECTION; LYMPHOSCINTIGRAPHY; MELANOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; WIDE EXCISION; COMPLETION LYMPHADENECTOMY; FEMALE; LYMPH NODE METASTASIS; MALE; METHODOLOGY; PATHOLOGY; SKIN TUMOR;

COMPLETION LYMPHADENECTOMY; MELANOMA; SENTINEL LYMPH NODE BIOPSY; WIDE LOCAL EXCISION;

FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 84907661693     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2014.07.002     Document Type: Review

References (58)

1. Miller A.J., Mihm M.C. Melanoma. NEngl J Med 2006, 355(1):51-65.
2. Balch C.M., Gershenwald J.E., Soong S.J., et al. Final version of 2009 AJCC melanoma staging and classification. JClin Oncol 2009, 27(36):6199-6206.
3. American Cancer Society Cancer Facts & Figures 2014 2014, American Cancer Society, Atlanta (GA).
4. Linos E., Swetter S.M., Cockburn M.G., et al. Increasing burden of melanoma in the United States. JInvest Dermatol 2009, 129(7):1666-1674.
5. Neuhaus S.J., Clark M.A., Thomas J.M. Dr. Herbert Lumley Snow, MD, MRCS (1847-1930): the original champion of elective lymph node dissection in melanoma. Ann Surg Oncol 2004, 11(9):875-878.
6. Norris W. Eight cases of melanosis with pathological and therapeutic remarks on that disease 1857, Longman, Brown, Green, Longman, and Roberts, London.
7. Eedy D.J. Surgical treatment of melanoma. Br J Dermatol 2003, 149(1):2-12.
8. Wong C.K. Astudy of melanocytes in the normal skin surrounding malignant melanomata. Dermatologica 1970, 141(3):215-225.
9. Ross M.I., Gershenwald J.E. Evidence-based treatment of early-stage melanoma. JSurg Oncol 2011, 104(4):341-353.
10. Breslow A., Macht S.D. Optimal size of resection margin for thin cutaneous melanoma. Surg Gynecol Obstet 1977, 145(5):691-692.
11. Bichakjian C.K., Halpern A.C., Johnson T.M., et al. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. JAm Acad Dermatol 2011, 65(5):1032-1047.
12. Lens M.B., Nathan P., Bataille V. Excision margins for primary cutaneous melanoma: updated pooled analysis of randomized controlled trials. Arch Surg 2007, 142(9):885-891. [discussion: 891-3].
13. Cascinelli N. Margin of resection in the management of primary melanoma. Semin Surg Oncol 1998, 14(4):272-275.
14. Cohn-Cedermark G., Rutqvist L.E., Andersson R., et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000, 89(7):1495-1501.
15. Khayat D., Rixe O., Martin G., et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 2003, 97(8):1941-1946.
16. Balch C.M., Soong S.J., Smith T., et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001, 8(2):101-108.
17. Thomas J.M., Newton-Bishop J., A'Hern R., et al. Excision margins in high-risk malignant melanoma. NEngl J Med 2004, 350(8):757-766.
18. Gillgren P., Drzewiecki K.T., Niin M., et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet 2011, 378(9803):1635-1642.
19. Heaton K.M., Sussman J.J., Gershenwald J.E., et al. Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma. Ann Surg Oncol 1998, 5(4):322-328.
20. Pasquali S., Haydu L.E., Scolyer R.A., et al. The importance of adequate primary tumor excision margins and sentinel node biopsy in achieving optimal locoregional control for patients with thick primary melanomas. Ann Surg 2013, 258(1):152-157.
21. Mocellin S., Pasquali S., Nitti D. The impact of surgery on survival of patients with cutaneous melanoma: revisiting the role of primary tumor excision margins. Ann Surg 2011, 253(2):238-243.
22. Sober A.J. Diagnosis and management of early melanoma: a consensus view. Semin Surg Oncol 1993, 9(3):194-197.
23. Kunishige J.H., Brodland D.G., Zitelli J.A. Margins for standard excision of melanoma in situ. JAm Acad Dermatol 2013, 69(1):164.
24. Santillan A.A., Messina J.L., Marzban S.S., et al. Pathology review of thin melanoma and melanoma in situ in a multidisciplinary melanoma clinic: impact on treatment decisions. JClin Oncol 2010, 28(3):481-486.
25. Balch C.M., Soong S., Ross M.I., et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000, 7(2):87-97.
26. Cascinelli N., Morabito A., Santinami M., et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998, 351(9105):793-796.
27. Robinson D.S., Sample W.F., Fee H.J., et al. Regional lymphatic drainage in primary malignant melanoma of the trunk determined by colloidal gold scanning. Surg Forum 1977, 28:147-148.
28. Morton D.L., Wen D.R., Wong J.H., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992, 127(4):392-399.
29. Gershenwald J.E., Thompson W., Mansfield P.F., et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. JClin Oncol 1999, 17(3):976-983.
30. Gershenwald J.E., Ross M.I. Sentinel-lymph-node biopsy for cutaneous melanoma. NEngl J Med 2011, 364(18):1738-1745.
31. Valsecchi M.E., Silbermins D., de Rosa N., et al. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. JClin Oncol 2011, 29(11):1479-1487.
32. Morton D.L., Cochran A.J., Thompson J.F., et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005, 242(3):302-311. [discussion: 311-3].
33. Wrightson W.R., Wong S.L., Edwards M.J., et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol 2003, 10(6):676-680.
34. Morton D.L., Thompson J.F., Cochran A.J., et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. NEngl J Med 2014, 370(7):599-609.
35. Wong S.L., Balch C.M., Hurley P., et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. JClin Oncol 2012, 30(23):2912-2918.
36. Scoggins C.R., Bowen A.L., Martin R.C., et al. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma. Arch Surg 2010, 145(7):622-627.
37. Criscione V.D., Weinstock M.A. Melanoma thickness trends in the United States, 1988-2006. JInvest Dermatol 2010, 130(3):793-797.
38. Andtbacka R.H., Gershenwald J.E. Role of sentinel lymph node biopsy in patients with thin melanoma. JNatl Compr Canc Netw 2009, 7(3):308-317.
39. Balch C.M., Gershenwald J.E., Soong S.J., et al. Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate. JSurg Oncol 2011, 104(4):379-385.
40. Rousseau D.L., Ross M.I., Johnson M.M., et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 2003, 10(5):569-574.
41. Yonick D.V., Ballo R.M., Kahn E., et al. Predictors of positive sentinel lymph node in thin melanoma. Am J Surg 2011, 201(3):324-327. [discussion: 327-8].
42. Han D., Zager J.S., Shyr Y., et al. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. JClin Oncol 2013, 31(35):4387-4393.
43. Vaquerano J., Kraybill W.G., Driscoll D.L., et al. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol 2006, 13(2):198-204.
44. Sondak V.K., Wong S.L., Gershenwald J.E., et al. Evidence-based clinical practice guidelines on the use of sentinel lymph node biopsy in melanoma. Am Soc Clin Oncol Educ Book 2013, 320-325.
45. Kesmodel S.B., Karakousis G.C., Botbyl J.D., et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 2005, 12(6):449-458.
46. McMasters K.M., Chao C., Wong S.L., et al. Interval sentinel lymph nodes in melanoma. Arch Surg 2002, 137(5):543-547. [discussion: 547-9].
47. McMasters K.M., Reintgen D.S., Ross M.I., et al. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed?. Ann Surg Oncol 2001, 8(3):192-197.
48. Wong S.L., Morton D.L., Thompson J.F., et al. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol 2006, 13(6):809-816.
49. Morton D.L., Thompson J.F., Cochran A.J., et al. Sentinel-node biopsy or nodal observation in melanoma. NEngl J Med 2006, 355(13):1307-1317.
50. McMasters K.M., Noyes R.D., Reintgen D.S., et al. Lessons learned from the Sunbelt Melanoma Trial. JSurg Oncol 2004, 86(4):212-223.
51. van der Ploeg A.P., van Akkooi A.C., Verhoef C., et al. Completion lymph node dissection after a positive sentinel node: no longer a must?. Curr Opin Oncol 2013, 25(2):152-159.
52. Bilimoria K.Y., Balch C.M., Bentrem D.J., et al. Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States. Ann Surg Oncol 2008, 15(6):1566-1576.
53. Nagaraja V., Eslick G.D. Is complete lymph node dissection after a positive sentinel lymph node biopsy for cutaneous melanoma always necessary? A meta-analysis. Eur J Surg Oncol 2013, 39(7):669-680.
54. Murali R., Desilva C., Thompson J.F., et al. Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. JClin Oncol 2010, 28(29):4441-4449.
55. Cadili A., McKinnon G., Wright F., et al. Validation of a scoring system to predict non-sentinel lymph node metastasis in melanoma. JSurg Oncol 2010, 101(3):191-194.
56. Prens S.P., van der Ploeg A.P., van Akkooi A.C., et al. Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site. Ann Surg Oncol 2011, 18(13):3586-3592.
57. Lee C.C., Faries M.B., Wanek L.A., et al. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. JClin Oncol 2008, 26(4):535-541.
58. Mack L.A., McKinnon J.G. Controversies in the management of metastatic melanoma to regional lymphatic basins. JSurg Oncol 2004, 86(4):189-199.